CD14 and melanoma: Previously, a novel population of MDSCs, termed cluster of differentiation 14 (CD14)+ human leukocyte antigen (HLA)-DRlow/− MDSCs, were identified in melanoma, hepatocarcinoma and B-cell non-Hodgkin lymphoma patients (4–6), indicating that low or lacking HLA-DR expression is associated with a CD14+ cell subset, which is highly suppressive of lymphocyte function.